AD is a progressive neurodegenerative disorder and a leading cause of dementia in an
aging population worldwide. The enormous challenge which AD possesses to global …

To date, studies suggest that biological signaling by nitric oxide (NO) is primarily mediated
by cGMP, which is synthesized by NO-activated guanylyl cyclases and broken down by …

Abstract When Furchgott, Murad, and Ignarro were honored with the Nobel prize for the
identification of nitric oxide (NO) in 1998, the therapeutic implications of this discovery could …

Cyclic nucleotide phosphodiesterases (PDEs) that specifically inactivate the intracellular
messengers cAMP and cGMP in a compartmentalized manner represent an important …

Cyclic nucleotide-specific phosphodiesterases (PDEs) play a critical role in signal
transduction by regulating the level of adenosine 3′, 5′-cyclic monophosphate (cAMP) …

Cyclic nucleotide phosphodiesterases (PDEs) are enzymes that have the unique function of
terminating cyclic nucleotide signaling by catalyzing the hydrolysis of cAMP and GMP. They …

Introduction: Phosphodiesterase (PDE) inhibitors improve signaling pathways in brain
circuits by increasing intracellular cyclic adenosine monophosphate (cAMP) and/or cyclic …

Alzheimer's disease (AD) is the most common form of dementia among the elderly. In AD
patients, memory loss is accompanied by the formation of beta-amyloid plaques and the …

The nitric oxide (NO)/cGMP pathway has been extensively studied for its pivotal role in
synaptic plasticity and memory processes, resulting in an increase of cAMP response …

Cognitive deficits in schizophrenia are among the core symptoms of the disease, correlate
with functional outcome, and are not well treated with current antipsychotic therapies. In …